Skip to content

Read More

The art of the possible: Charlie Hurt on the Trump-Musk cosmic bromance

Advertisement

These illustrations, provided by drugmaker ViiV Healthcare on Thursday, Dec. 10, 2020, shows a rendering of the packaging and vials containing its new HIV treatment, Cabenuva, approved by the U.S. Food and Drug Administration on Thursday, Jan. 21, 2021. U.S. regulators have approved the first long-acting combo drug for HIV, monthly shots that can replace the daily pills that have been used for decades to control infection with the AIDS virus. Thursday’s approval of Cabenuva is expected to make it easier for people to stay on track with their HIV medicines and to do so with more privacy(ViiV Healthcare via AP)

These illustrations, provided by drugmaker ViiV Healthcare on Thursday, Dec. 10, 2020, shows a rendering of the packaging and vials containing its new HIV treatment, Cabenuva, approved by the U.S. Food and Drug Administration on Thursday, Jan. 21, 2021. U.S. regulators have approved the first long-acting combo drug for HIV, monthly shots that can replace the daily pills that have been used for decades to control infection with the AIDS virus. Thursday’s approval of Cabenuva is expected to make it easier for people to stay on track with their HIV medicines and to do so with more privacy(ViiV Healthcare via AP)

Featured Photo Galleries